TELA Bio, Inc. TELA
At closeNov 10, 2026, 4:50 PM EST
After hours · Nov 10, 4:50 PM ET
- YTD
- -32.20%
- 1 year
- -32.77%
- Market cap
- 36.11M
- Revenue (ttm)
- 68.65M
- Profit margin
- -60.49%
- EPS (ttm)
- -0.71
- Shares out
- 39.39M
- Forward P/E
- -4.31
- YTD return
- -32.20%
- 1-year return
- -32.77%
- Volume
- 121.31K
- Avg volume
- 219.18K
- Open
- 0.90
- Previous close
- 0.8646
- Day's range
- 0.80 – 0.9391
- 52-week range
- 0.501 – 1.50
- Beta
- 0.97
- Analysts
- Strong Buy
- Price target
- 9.20 (+1050.0%)
- Earnings date
- Aug 12, 2024
5D -0.0200 (-2.44%)
Key statistics
- Enterprise value
- 95.57M
- PEG ratio
- 0.00
- Price / sales
- 1.68
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 25.90%
- Free cash flow
- 0
- Total cash
- 17.30M
- Total debt
- 42.43M
- Return on equity
- -342.04%
- Short % of float
- 0.98%
- 50-day average
- 2.85
- 200-day average
- 4.02
Analyst view
Consensus: strong buy
- Target (low)
- 5.00
- Target (mean)
- 9.20
- Target (high)
- 12.00
- Strong buy2
- Buy3
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 12, 2024
Expected Aug 12, 2024. Consensus EPS estimate -0.222.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.37 | -0.42 | -0.05 | -13.51% |
| Aug 12, 2024 | Jun 1, 2024 | -0.45 | -0.51 | -0.06 | -13.33% |
| Aug 12, 2024 | Jun 1, 2024 | -0.45 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | -0.48 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | -0.48 | -0.23 | +0.25 | +52.08% |
| Mar 21, 2024 | Dec 1, 2023 | -0.44 | -0.53 | -0.09 | -20.45% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 8, 2024 | Piper Sandler | main | Overweight | Overweight |
| Oct 4, 2024 | Canaccord Genuity | main | Buy | Buy |
| Aug 13, 2024 | Lake Street | main | Buy | Buy |
| Aug 13, 2024 | Canaccord Genuity | main | Buy | Buy |
| Aug 13, 2024 | JMP Securities | main | Market Outperform | Market Outperform |
| Aug 13, 2024 | Piper Sandler | main | Overweight | Overweight |
About TELA Bio, Inc.
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- telabio.com
News
TELA Bio, Inc. (TELA) Q3 2026 Earnings Call Transcript 
TELA Bio, Inc. (TELA) Reports Q3 Loss, Beats Revenue Estimates 
TELA Bio Q3 2026 Earnings Call Transcript 
TELA Bio Reports Third Quarter 2026 Financial Results 
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 
TELA Bio to Announce Third Quarter 2026 Financial Results 
TELA Bio, Inc. (TELA) Shareholder/Analyst Call Transcript 
TELA Bio Announces 510(k) Clearance for Liora™ Monofilament Scaffold for Soft Tissue Reinforcement 
5 Stock Picks Last Week From Wall Street's Most Accurate Analysts 
Craig-Hallum Initiates Coverage On TELA Bio with Buy Rating, Announces Price Target of $2
Your note
Sign in to keep a note on TELA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| AZARBARZIN KURT | Director | Stock Award(Grant) | Jun 3, 2024 | 10,520 |
| BURGESS VINCENT J | Director | Stock Award(Grant) | Jun 3, 2024 | 15,380 |
| COLLERAN LISA N | Director | Stock Award(Grant) | Jun 3, 2024 | 10,520 |
| CUCA ROBERTO | Chief Operating Officer | Purchase | Oct 23, 2024 | 155,388 |
| EVANS DOUGLAS G | Director | Stock Award(Grant) | Jun 3, 2024 | 10,520 |
| FIRESTONE GREGORY A | Officer | Purchase | Oct 23, 2024 | 57,279 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Essex Woodlands Management Inc. | 10.44% | 4,110,709 | 12.04M | Sep 29, 2024 |
| AIGH Capital Management LLC | 6.27% | 2,469,373 | 7.24M | Sep 29, 2024 |
| Orbimed Advisors LLC. | 5.49% | 2,161,185 | 6.33M | Sep 29, 2024 |
| Nantahala Capital Management, LLC | 4.86% | 1,915,126 | 5.61M | Sep 29, 2024 |
| SilverArc Capital Management, LLC | 2.86% | 1,124,928 | 3.30M | Sep 29, 2024 |
| Stonepine Capital Management, LLC | 2.82% | 1,110,000 | 3.25M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.63% | 643,290 | 1.88M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.58% | 226,799 | 664.52K | Sep 29, 2024 |
| Federated Hermes Kaufmann Fund | 0.39% | 153,969 | 451.13K | Jul 30, 2024 |
| Jacob Discovery Fd | 0.35% | 139,775 | 409.54K | Oct 30, 2024 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.26% | 101,000 | 295.93K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.21% | 81,201 | 237.92K | Oct 30, 2024 |